A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : BiTE

Search Conditions:
Search Keyword : BiTE
Search Method : Exact match.
Research Area:

Abbreviation: BiTE
Appearance Frequency: 192 time(s)
Long forms: 8

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
bispecific T-cell engager
(180 times)
(71 times)
CAR (33 times)
ALL (28 times)
AML (15 times)
2005 Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
bispecific antibody construct
(3 times)
(1 time)
ADCC (1 time)
CAR-T (1 time)
CS (1 time)
2015 Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines invitro.
bispecific T cell-engaging antibodies
(3 times)
Immune System Diseases
(1 time)
BsAbs (1 time)
EMA (1 time)
FDA (1 time)
2017 Bispecific antibodies for cancer therapy: A review.
bispecific antibody
(2 times)
(1 time)
CAR-T (1 time)
CD3 (1 time)
EpCAM (1 time)
2014 Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
biased tree ensembles
(1 time)
Natural Science Disciplines
(1 time)
GDSC (1 time)
MRPs (1 time)
NetBiTE (1 time)
2019 Network-based Biased Tree Ensembles (NetBiTE) for Drug Sensitivity Prediction and Drug Sensitivity Biomarker Identification in Cancer.
bispecific T-cell therapy
(1 time)
Translational Medical Research
(1 time)
CAR-T therapy (1 time)
cHL (1 time)
CTLA-4 (1 time)
2021 Immune checkpoint inhibitors in lymphoma: challenges and opportunities.
bispecific tumor-targeted Tcell engager
(1 time)
Molecular Biology
(1 time)
CAR (1 time)
CD44v6 (1 time)
IL (1 time)
2020 Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
CD3-bispecific T-cell receptor-engaging
(1 time)
(1 time)
CRS (1 time)
HLH (1 time)
2013 Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.